Anti‐inflammatory effects of high‐dose montelukast in an animal model of acute asthma
Authors:
- 5 March 2003
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 33 (3) , 359-366
Abstract
Summary: Background Asthmatic inflammation is mediated by a network of cytokines, chemokines and adhesion molecules. Corticosteroids are the only effective agents available to control asthmatic inflammation. We investigated the effect of high‐dose montelukast (MK), a selective cysteinyl leukotriene receptor 1 antagonist, on mediators of airway inflammation.Objective The aim of this study was to determine the effect of a 3‐day course of high‐dose MK on mediators of airway inflammation induced by a single allergen challenge in sensitized mice.Methods Ovalbumin (OVA)‐sensitized BALB/c mice were treated with 25 mg/kg of MK or saline intravenously for 3 days. On the third day, a single inhalation challenge with OVA was given. Cellular infiltration was assessed in the bronchoalveolar lavage (BAL) and in the lung. Expression of IL‐4, IL‐5, IL‐13 and eotaxin in the BAL, and the lung was determined. Serum IL‐5 and total IgE was measured. IL‐5 and eotaxin mRNA expression in the lung was determined. Finally, eotaxin and VACM‐1 expression in the lung was assessed by immunohistochemistry.Results MK reduced the number of eosinophils in the BAL by > 90%. There was also significant reduction in IL‐5 in the BAL, lung and the serum, and IL‐5 mRNA expression in the lung. IL‐4 level in the lung and BAL, and IL‐13 level in the lung also significantly decreased. Serum IgE level and lung VCAM‐1 expression was also significantly lower in treated animals, but eotaxin protein and mRNA expression in the lung remained unchanged.Conclusion MK exerts its anti‐inflammatory effect through the suppression of T helper type‐2 (Th2) cytokines. The use of high‐dose MK as an anti‐inflammatory agent in acute asthma should be further explored.Keywords
This publication has 41 references indexed in Scilit:
- Involvement of LTD4in allergic pulmonary inflammation in mice: modulation by cysLT1antagonist MK-571Prostaglandins, Leukotrienes and Essential Fatty Acids, 2000
- The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthmaClinical & Experimental Allergy, 1999
- Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors.Journal of Clinical Investigation, 1996
- Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody.Journal of Experimental Medicine, 1996
- Stat6 Is Required for Mediating Responses to IL-4 and for the Development of Th2 CellsImmunity, 1996
- Single dose pharmacokinetics, safety and tolerability of MK‐0476, a new leukotriene D4‐receptor antagonist, in healthy volunteers.British Journal of Clinical Pharmacology, 1995
- Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic AsthmaNew England Journal of Medicine, 1992
- Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsivenessJournal of Allergy and Clinical Immunology, 1991
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensNew England Journal of Medicine, 1989
- Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects.Thorax, 1984